Top

Published in:

01-10-2014 | Current Opinion

Ahead of Its Time? Reflecting on New Zealand’s Pharmac Following Its 20th Anniversary

Author: Robin Gauld

Published in: PharmacoEconomics | Issue 10/2014

Abstract

New Zealand’s Pharmaceutical Management Agency (Pharmac) was created in 1993. Unusual in international terms, Pharmac’s objective is to work within a fixed budget while ensuring the New Zealand public receives an adequate range of government-subsidised medicines. Following its 20th anniversary, this article reflects on Pharmac’s development and role within the New Zealand health system, various changes over time to the agency’s scope and activities, its performance and its present challenges.

Ragupathy R, Aaltonen K, Tordoff J, Norris P, Reith D. A three-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand. Pharmacoeconomics. 2012;30(11):1051–65.PubMedCrossRef

Gauld R. Revolving doors: New Zealand’s health reforms: the Saga continues. Wellington: Institute of Policy Studies and Health Services Research Centre; 2009.

Gauld R. New Zealand’s post-2008 health system reforms: toward re-centralization of organizational arrangements. Health Policy. 2012;106:110–3.PubMedCrossRef

Clark H. Pharmaceutical costs and regulation: from the Minister’s desk. In: Davis P, editor. For health or profit? Medicine, the pharmaceutical industry, and the state in New Zealand. Auckland: Oxford University Press; 1992. p. 53–74.

Wilson JQ. Bureaucracy: what government agencies do and why they do it. New York: Basic Books; 1989.

Pharmaceutical Management Agency. Pharmac’s decision criteria: consultation document. Wellington: Pharmaceutical Management Agency; 2013.

Grocott R. Applying programme budgeting marginal analysis in the health sector: 12 years of experience. Expert Rev Pharmacoecon Outcomes Res. 2009;9(2):181–7.PubMedCrossRef

Grocott R, Metcalfe S, Alexander P, Werner R. Assessing the value for money of pharmaceuticals in New Zealand: Pharmac’s approach to cost-utility analysis. N Z Med J. 2013;126(1378):60–73.PubMed

Goldacre B. Bad pharma: how drug companies mislead doctors and harm patients. London: Fourth Estate; 2012.

10.

Milne R, Wonder M. Response to Pharmac on access to new medicines in New Zealand compared to Australia. N Z Med J. 2011;124(1347):91–3.PubMed

11.

Rasiah D, Edwards R, Crampton P. Funding community medicines by exception: a descriptive epidemiological study from New Zealand. N Z Med J. 2012;125(1350):21–9.PubMed

12.

Coyle G. How does the operation of Pharmac’s ‘Community Exceptional Circumstances’ policy align with the distributive justice principles of fairness and equity as described by John Rawls and Amartya Sen? Auckland University of Technology PhD thesis; 2012.

13.

Manning J. Exceptional circumstances schemes and the social factors exclusion in healthcare rationing. Oxford Univ Commonwealth Law J. 2013;13(1):75–114.CrossRef

14.

Tordoff J, Norris P, Reith D. ‘Price management’ and its impact on hospital pharmaceutical expenditure and the availability of medicines in New Zealand. Value Health. 2008;11(7):1214–26.PubMedCrossRef

15.

OECD. Health at a Glance 2013. Paris: OECD; 2013.

16.

Pharmaceutical Management Agency. Pharmaceutical Management Agency. Annual Review 2013. Wellington: Pharmaceutical Management Agency; 2013.

17.

OECD. OECD Health Data. Paris: OECD; 2013.

18.

The US health system in perspective: a comparison of twelve industrialized nations. New York: Commonwealth Fund; 2011.

19.

Cobiac L. Pharmac looks great value for money: an Australian perspective. N Z Med J. 2012;125(1358):82–3.PubMed

20.

Duckett S, Breadon P, Ginnivan L, Venkararaman P. Australia’s bad drug deal: high pharmaceutical prices. Melbourne: Grattan Institute; 2013.

21.

Fenton E. Making fair funding decisions for high cost cancer care: the case of herceptin in New Zealand. Public Health Ethics. 2010;3(2):137–46.CrossRef

22.

Wonder M, Milne R. Access to new medicines in New Zealand compared to Australia. N Z Med J. 2011;124(1346):12–28.PubMed

23.

Moodie P, Metcalfe S, Poynton M. Do pharmaceutical score cards give us the answers we seek? N Z Med J. 2011;124(1346):69–74.PubMed

24.

Cumming J, Mays N, Daube J. How New Zealand has contained expenditure on drugs. BMJ. 2010;340(c2441):1224–7.

25.

Begg E, Sidwell A, Gardiner S, Nicholls G, Scott R. The sorry saga of the statins in New Zealand: pharmacopolitics versus patient care. N Z Med J. 2003;116(1170):U360.PubMed

26.

Ellis CJ, White H. Pharmac and the statin debacle. N Z Med J. 2006;119(1236).

27.

Moodie P, Dougherty S, Metcalfe S. Pharmac and statins: getting the best population health gains. N Z Med J. 2006;119(1238):1–3.

28.

Gleeson D, Lopert R, Reid P. How the Trans Pacific Partnership Agreement could undermine Pharmac and threaten access to affordable medicines and health equity in New Zealand. Health Policy. 2013;112:227–33.PubMedCrossRef

29.

Davis P. Tough but fair? The active management of the New Zealand Drug Benefits Scheme by an independent crown agency. Aust Health Rev. 2004;28(2):171–81.PubMedCrossRef

Title: Ahead of Its Time? Reflecting on New Zealand’s Pharmac Following Its 20th Anniversary
Author: Robin Gauld
Publication date: 01-10-2014
Publisher: Springer International Publishing
Published in: PharmacoEconomics / Issue 10/2014
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI: https://doi.org/10.1007/s40273-014-0178-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Ahead of Its Time? Reflecting on New Zealand’s Pharmac Following Its 20th Anniversary

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2014

Avoiding and Identifying Errors and Other Threats to the Credibility of Health Economic Models

Modelling Outcomes of Complex Treatment Strategies Following a Clinical Guideline for Treatment Decisions in Patients with Rheumatoid Arthritis

Reconceptualising the External Validity of Discrete Choice Experiments

Cost–Utility Analysis of Chemotherapy Regimens in Elderly Patients with Stage III Colon Cancer

Network vs. Pairwise Meta-Analyses: A Case Study of the Impact of an Evidence-Synthesis Paradigm on Value of Information Outcomes

Comment on “Ahead of Its Time? Reflecting on New Zealand’s Pharmac Following its 20th Anniversary”